Comparison of 1.0 M gadobutrol and 0.5 M gadopentate dimeglumine-enhanced MRI in 471 patients with known or suspected renal lesions: Results of a multicenter, single-blind, interindividual, randomized clinical phase III trial

European Radiology

Volumn 18, Issue 11, 2008, Pages 2610-2619

  Tombach, Bernd ^a,b   Bohndorf, Klaus ^c   Brodtrager, Wolfgang ^aa   Claussen, Claus D ^d   Düber, Christoph ^e   Galanski, Michael ^f   Grabbe, Eckhardt ^g   Gortenuti, Giacomo ^h   Kuhn, Michael ⁱ   Gross Fengels, Walter ⁱ   Hammerstingl, Renate ^z   Happel, Brigitte ^j   Heinz Peer, Gertraud ^j   Jung, Gregor ^l   Kittner, Thomas ^m   Lagalla, Roberto ⁿ   Lengsfeld, Philipp ^r   Loose, Reinhard ^o   Oyen, Raymond H G ^p   Pavlica, Pietro ^q   Pering, Christiane ^r   Pozzi Mucelli, Roberto ^s   Persigehl, Thorsten ^b   Reimer, Peter ^t   Renken, Nomdo S ^u   Richter, Götz M ^v   Rummeny, Ernst J ^w   Schäfer, Fritz ^k   Szczerbo Trojanowska, Malgorzata ^x   Urbanik, Andrzej ^y   Vogl, Thomas J ^z   Hajek, Paul ^aa   more..

^a Andreas Bannowsky Ltd   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c KLINIKUM AUGSBURG   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g UNIVERSITY OF GÖTTINGEN   (Germany)

^h MAGGIORE HOSPITAL   (Italy)

ⁱ Allgemeines Krankenhaus Eilbek   (Germany)

^j MEDICAL UNIVERSITY OF VIENNA   (Austria)

^k UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^l Institut für Diagnostische und Interventionelle Radiologie   (Germany)

^m UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

ⁿ UNIVERSITY OF PALERMO   (Italy)

^o KLINIKUM NÜRNBERG   (Germany)

^p UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^q Ospedale M Malpighi   (Italy)

^r BAYER PHARMA AG   (Germany)

^s UNIVERSITY OF TRIESTE   (Italy)

^t STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^u ERASMUS MEDICAL CENTER   (Netherlands)

^v UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^w TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^x Zabiegowej i Neuroradiologii   (Poland)

^y JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^z UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^aa AÖKH WienerNeustadt ^*  (Austria)

more..

Author keywords

Diagnostic differentiation; Gadobutrol; Gadopentate dimeglumine; MRI; Noninferiority; Renal lesions

Indexed keywords

GADOBUTROL; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE;

ADULT; ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; IMAGE ENHANCEMENT; IMAGE RECONSTRUCTION; INTERMETHOD COMPARISON; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE;

CONTRAST MEDIA; EUROPE; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; KIDNEY NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SINGLE-BLIND METHOD;

EID: 54049123679     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-008-1054-2     Document Type: Article

References (31)

1. Francis IR (2006) Detection, staging and surveillance in renal cell carcinoma. Cancer Imaging 6:168-174
2. Semelka RC, Hricak H, Stevens SK, Finegold R, Tomei E, Carroll PR (1991) Combined gadolinium-enhanced and fat-saturation MR imaging of renal masses. Radiology 178:803-809
3. Krestin GP (1999) Genitourinary MR: Kidneys and adrenal glands. Eur Radiol 9:1705-1714
4. Krestin GP (2001) Kidneys and adrenal glands. In: Felix R, Heshiki A, Hricak H, Chang KH (eds) Magnevist monograph. Blackwell Science, Berlin, pp 147-1534
5. Scattoni V, Da Pozzo LF, Colombo R, Nava L, Rigatti P, De Cobelli F, Vanzulli A, Del Maschio A (1996) Dynamic gadolinium-enhanced magnetic resonance imaging in staging of superficial bladder cancer. J Urol 155:1594-1599
6. Goyen M, Herborn CU, Vogt FM, Kroger K, Verhagen R, Yang F, Bosk S, Debatin JF, Ruehm SG (2003) Using a 1 M Gd-chelate (gadobutrol) for total-body three-dimensional MR angiography: Preliminary experience. J Magn Reson Imaging 17:565-571
7. Tombach B, Benner T, Reimer P, Schuierer G, Fallenberg EM, Geens V, Wels T, Sorensen AG (2003) Do highly concentrated gadolinium chelates improve MR brain perfusion imaging? Intraindividually controlled randomized crossover concentration comparison study of 0.5 versus 1.0 mol/L gadobutrol. Radiology 226:880-888
8. Tombach B (2004) Whole-body CE-MRA with gadovist. Eur Radiol 14(S5):M26-M27
9. Vosshenrich R, Engeroff B, Obenauer S, Grabbe E (2003) Contrast-enhanced MR angiography of the arterial and portovenous system of the liver with varying concentrations of contrast medium. Rofo 175:1239-1243
10. Hentsch A, Aschauer MA, Balzer JO, Brossmann J, Busch HP, Davis K, Douek P, Ebner F, van Engelshoven JM, Gregor M, Kersting C, Knusel PR, Leen E, Leiner T, Loewe C, McPherson S, Reimer P, Schafer FK, Taupitz M, Thurnher SA, Tombach B, Wegener R, Weishaupt D, Meaney JF (2003) Gadobutrol-enhanced moving-table magnetic resonance angiography in patients with peripheral vascular disease: A prospective, multi-centre blinded comparison with digital subtraction angiography. Eur Radiol 13:2103-2114
11. Huppertz A, Rohrer M (2004) Gadobutrol, a highly concentrated MR-imaging contrast agent: Its physicochemical characteristics and the basis for its use in contrast-enhanced MR angiography and perfusion imaging. Eur Radiol 14(S5):M12-M18
12. Schaefer FK, Schaefer PJ, Altjohann C, Bourne M, Decobelli F, Goyen M, Griffiths PD, Kopka L, Kreitner KF, Link J, Oberholzer K, Pering C, Poeckler-Schoeninger C, Ruehm SG, Sachoran MR, Schulte-Altedorneburg G, Springer OS, Steiner P, Wall A, Winterer J, Tombach B (2007) A multicenter, site-independent, blinded study to compare the diagnostic accuracy of contrast-enhanced magnetic resonance angiography using 1.0 M gadobutrol (Gadovist) to intraarterial digital subtraction angiography in body arteries. Eur J Radiol 61:315-323
13. Goyen M, Lauenstein TC, Herborn CU, Debatin JF, Bosk S, Ruehm SG (2001) 0.5 M Gd chelate (Magnevist) versus 1.0 M Gd chelate (Gadovist): dose-independent effect on image quality of pelvic three-dimensional MR-angiography. J Magn Reson Imaging 14:602-607
14. Herborn CU, Lauenstein TC, Ruehm SG, Bosk S, Debatin JF, Goyen M (2003) Intraindividual comparison of gadopentetate dimeglumine, gadobenate dimeglumine, and gadobutrol for pelvic 3D magnetic resonance angiography. Invest Radiol 38:27-33
15. Grobner T (2006) Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1104-1108
16. Thomsen HS, Morcos SK, Dawson P (2006) Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)? Clin Radiol 61:905-906
17. Khurram M, Skov L, Rossen K, Thomsen HS, Marckmann P (2007) Nephrogenic systemic fibrosis: A serious iatrogenic disease of renal failure patients. Scand J Urol Nephrol 1-2
18. Staks T, Schuhmann-Giampieri G, Frenzel T, Weinmann HJ, Lange L, Platzek J (1994) Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest Radiol 29:709-715
19. Schmitt-Willich H (2007) Stability of linear and macrocyclic gadolinium based contrast agents. Br J Radiol 80:581-582
20. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ (2005) Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 40:715-724
21. Tombach B (2000) Pharmacokinetics of 1 M gadobutrol in patients with chronic renal failure. Invest Radiol 35:35-40
22. Tombach B, Bremer C, Reimer P, Kisters K, Schaefer RM, Geens V, Heindel W (2001) Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: Results of a randomized study. Radiology 218:651-657
23. Tombach B, Bremer C, Reimer P, Matzkies F, Schaefer RM, Ebert W, Geens V, Eisele J, Heindel W (2002) Using highly concentrated gadobutrol as an MR contrast agent in patients also requiring hemodialysis: Safety and dialysability. AJR Am J Roentgenol 178:105-109
24. Knopp MV, Balzer T, Esser M, Kashanian FK, Paul P, Niendorf HP (2006) Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use. Invest Radiol 41:491-499
25. Deo A, Fogel M, Cowper SE (2007) Nephrogenic systemic fibrosis: A population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2:264-267
26. Todd DJ, Kagan A, Chibnik LB, Kay J (2007) Cutaneous changes of nephrogenic systemic fibrosis: Predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 56:3433-3441
27. Obuchowski NA (1998) Sample size calculations in studies of test accuracy. Stat Methods Med Res 7:371-392
28. Walter C (2003) Imaging of renal lesions: Evaluation of fast MRI and helical CT. Br J Radiol 76:696-703
29. Beer AJ (2006) Comparison of 16-MDCT and MRI for characterization of kidney lesions. AJR Am J Roentgenol 186:1639-1650
30. Sankoh AJ, Huque MF, Dubey SD (1997) Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Stat Med 16:2529-2542
31. Friedmann G, Krestin GP, Engelking R, Vorreuther R (1988) Importance of rapid MR imaging for tumor diagnosis in the area of the kidneys and adrenals. Rofo 148:143-149